Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects

Cancer Science

Volumn 106, Issue 4, 2015, Pages 337-343

  Omoto, Yoko ^a,b,c   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Tanabe Central Hospital   (Japan)

Author keywords

Breast cancer; Estrogen receptor alpha; Estrogen receptor beta; Hormone therapy; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 2; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN;

BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; DNA BINDING; HUMAN; LIGAND BINDING; MALE; MCF 7 CELL LINE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; RAT MODEL; RECEPTOR AFFINITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENETICS; METABOLISM; MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MALE; MCF-7 CELLS; MICE; PROSTATIC NEOPLASMS;

EID: 84928048056     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12613     Document Type: Review

References (76)

1. Oliveira AG, Coelho PH, Guedes FD, Mahecha GA, Hess RA, Oliveira CA. 5alpha-Androstane-3beta, 17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats. Steroids 2007; 72: 914-22.
2. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A 2002; 99: 13589-94.
3. Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 1993; 7: 1266-74.
4. Walter P, Green S, Greene G et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A 1985; 82: 7889-93.
5. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93: 5925-30.
6. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997; 11: 1569-80.
7. Superti-Furga G, Bergers G, Picard D, Busslinger M. Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins. Proc Natl Acad Sci U S A 1991; 88: 5114-8.
8. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508-10.
9. Webb P, Nguyen P, Valentine C et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999; 13: 1672-85.
10. Ogawa S, Inoue S, Watanabe T et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 1998; 26: 3505-12.
11. Chu S, Fuller PJ. Identification of a splice variant of the rat estrogen receptor beta gene. Mol Cell Endocrinol 1997; 132: 195-9.
12. Petersen DN, Tkalcevic GT, Koza-Taylor PH, Turi TG, Brown TA. Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues. Endocrinology 1998; 139: 1082-92.
13. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003; 22: 5011-20.
14. Cheng G, Weihua Z, Warner M, Gustafsson JA. Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A 2004; 101: 3739-46.
15. Palmieri C, Saji S, Sakaguchi H et al. The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. J Mol Endocrinol 2004; 33: 35-50.
16. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 2002; 55: 371-4.
17. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423-8.
18. Behrens D, Gill JH, Fichtner I. Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 2007; 274: 19-29.
19. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006; 66: 11207-13.
20. Helguero LA, Lindberg K, Gardmo C, Schwend T, Gustafsson JA, Haldosen LA. Different roles of estrogen receptors alpha and beta in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 2008; 68: 8695-704.
21. Lin CY, Strom A, Li Kong S et al. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007; 9: R25.
22. Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A 2000; 97: 337-42.
23. Forster C, Makela S, Warri A et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 2002; 99: 15578-83.
24. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001; 61: 2537-41.
25. Omoto Y, Kobayashi S, Inoue S et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002; 38: 380-6.
26. Honma N, Horii R, Iwase T et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727-34.
27. Huang B, Omoto Y, Iwase H et al. Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A 2014; 111: 1933-8.
28. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004; 10: 7490-9.
29. Iwase H, Zhang Z, Omoto Y et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): S34-8.
30. Murphy LC, Peng B, Lewis A et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34: 553-66.
31. Cappelletti V, Celio L, Bajetta E et al. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer 2004; 11: 761-70.
32. Shaaban AM, Green AR, Karthik S et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008; 14: 5228-35.
33. Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP. Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer-a retrospective study. BMC Cancer 2007; 7: 131.
34. Saji S, Omoto Y, Shimizu C et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 2002; 62: 4849-53.
35. Huggins C. Endocrine control of prostatic cancer. Science 1943; 97: 541-4.
36. Horning ES. The effects of castration and stilboestrol on prostatic tumours in mice. Br J Cancer 1949; 3: 211-30.
37. Barnes RW, Emery DS. Management of early prostatic carcinoma. Calif Med 1959; 91: 57-61.
38. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 2001; 61: 6089-97.
39. Omoto Y. Estrogen receptor-alpha signaling in growth of the ventral prostate: comparison of neonatal growth and postcastration regrowth. Endocrinology 2008; 149: 4421-7.
40. Horvath LG, Henshall SM, Lee CS et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61: 5331-5.
41. Prins GS, Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 1997; 138: 1801-9.
42. Omoto Y, Imamov O, Warner M, Gustafsson JA. Estrogen receptor alpha and imprinting of the neonatal mouse ventral prostate by estrogen. Proc Natl Acad Sci U S A 2005; 102: 1484-9.
43. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60: 3175-82.
44. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004; 566: 169-72.
45. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 2002; 8: 1003-7.
46. Dey P, Jonsson P, Hartman J, Williams C, Strom A, Gustafsson JA. Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012; 26: 1991-2003.
47. Pasquali D, Staibano S, Prezioso D et al. Estrogen receptor beta expression in human prostate tissue. Mol Cell Endocrinol 2001; 178: 47-50.
48. Leav I, Lau KM, Adams JY et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
49. Fujimura T, Takahashi S, Urano T et al. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 2001; 289: 692-9.
50. Thellenberg-Karlsson C, Lindstrom S, Malmer B et al. Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006; 12: 1936-41.
51. Attia DM, Ederveen AG. Opposing roles of ERalpha and ERbeta in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate 2012; 72: 1013-22.
52. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009; 55: 533-42.
53. Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G. Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol 2010; 184: 2172-8.
54. Chang WY, Prins GS. Estrogen receptor-beta: implications for the prostate gland. Prostate 1999; 40: 115-24.
55. Muthusamy S, Andersson S, Kim HJ et al. Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci U S A 2011; 108: 20090-4.
56. Weihua Z, Makela S, Andersson LC et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 2001; 98: 6330-5.
57. Imamov O, Morani A, Shim GJ et al. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci U S A 2004; 101: 9375-80.
58. Mak P, Leav I, Pursell B et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17: 319-32.
59. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 2009; 1155: 174-86.
60. Risbridger G, Wang H, Young P et al. Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium. Dev Biol 2001; 229: 432-42.
61. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008; 22: 1512-20.
62. McPherson SJ, Hussain S, Balanathan P et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci U S A 2010; 107: 3123-8.
63. Dondi D, Piccolella M, Biserni A et al. Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta, 17beta-diol. Endocr Relat Cancer 2010; 17: 731-42.
64. Guerini V, Sau D, Scaccianoce E et al. The androgen derivative 5alpha-androstane-3beta, 17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 2005; 65: 5445-53.
65. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002; 186: 89-99.
66. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002; 132: 552S-8S.
67. Slater M, Brown D, Husband A. In the prostatic epithelium, dietary isoflavones from red clover significantly increase estrogen receptor beta and E-cadherin expression but decrease transforming growth factor beta1. Prostate Cancer Prostatic Dis 2002; 5: 16-21.
68. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discovery 2011; 10: 778-92.
69. Pravettoni A, Mornati O, Martini PG et al. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 2007; 263: 46-54.
70. Savolainen S, Pakarainen T, Huhtaniemi I, Poutanen M, Makela S. Delay of postnatal maturation sensitizes the mouse prostate to testosterone-induced pronounced hyperplasia: protective role of estrogen receptor-beta. Am J Pathol 2007; 171: 1013-22.
71. Dey P, Strom A, Gustafsson JA. Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene 2014; 33: 4213-25.
72. Toren P, Zoubeidi A. Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). Int J Oncol 2014; 45: 1793-801.
73. Wang LJ, Han SX, Bai E et al. Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways. Oncol Rep 2013; 29: 1563-9.
74. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 2014; 40: 862-71.
75. Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer 2014; 6: 43-57.
76. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.